^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Title:

Anti-Glypican-1 Antibody–drug Conjugate as Potential Therapy Against Tumor Cells and Tumor Vasculature for Glypican-1–Positive Cholangiocarcinoma

Published date:
09/01/2021
Excerpt:
In this study, we confirmed that GPC1 was highly expressed in cholangiocarcinoma cells and tissues....MMAF-conjugated GPC1–ADC showed potent tumor growth inhibition against GPC1-positive cholangiocarcinoma cells in vitro and in vivo….Vascular endothelial cells in tumor tissues of GPC1-negative xenograft mice expressed GPC1 and were arrested in the G2–M phase of cell cycle by GPC1–ADC. GPC1–ADC exhibits direct as well as indirect antitumor effects via inhibition of tumor angiogenesis. Our preclinical data highlight GPC1–ADC as a promising therapy for GPC1-positive cholangiocarcinoma.
DOI:
https://doi.org/10.1158/1535-7163.MCT-21-0015
Evidence Level:
Sensitive: D – Preclinical
New
Source:
Title:

Abstract 4833: Antibody-drug conjugate targeting glypican-1 shows tumor growth inhibition in cholangiocarcinoma

Excerpt:
KKU-055 and KKU-100 cells, which are cell lines of cholangiocarcinoma, had high expression of GPC1….GPC1-ADC showed potent antitumor effect toward KKU-055 and KKU-100 cells compared with the control ADC. In the KKU-055 xenograft model, GPC1-ADC had significant and potent tumor growth inhibition in a dose-dependent manner. In summary, our newly-developed GPC1-ADC showed significant tumor growth inhibition against GPC1-positive cholangiocarcinoma cell lines. Our preclinical data demonstrated that targeting GPC1 by ADC is a promising therapy for GPC1-positive cholangiocarcinoma.
DOI:
https://doi.org/10.1158/1538-7445.AM2019-4833